Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Chugai Pharmaceutical Co., Ltd
  6. News
  7. All News
    4519   JP3519400000

CHUGAI PHARMACEUTICAL CO., LTD

(4519)
  Report
Delayed Japan Exchange  -  01:00:00 2023-02-02 am EST
3296.00 JPY   -0.87%
02:40aChugai Pharmaceutical : Full Year Results (Jan-Dec 2022)
PU
02/01Chugai Pharmaceutical : Hemlibra Approved by the European Commission to Treat People with Moderate Hemophilia
PU
01/17Japan's Nikkei rises as investors brace for BOJ decision
RE
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news
All news about CHUGAI PHARMACEUTICAL CO., LTD
02:40aChugai Pharmaceutical : Full Year Results (Jan-Dec 2022)
PU
02/01Chugai Pharmaceutical : Hemlibra Approved by the European Commission to Treat People with ..
PU
01/17Japan's Nikkei rises as investors brace for BOJ decision
RE
2022Japan's Nikkei ends flat, posts first annual loss in 4 years
RE
2022Japanese shares track Wall Street rise, caution ahead of holiday caps gains
RE
2022CHUGAI PHARMACEUTICAL CO., LTD : Ex-dividend day for fina..
FA
2022Chugai Pharmaceutical : The Launch of Chugai's New TV Commercial Featuring Tori Matsuzaka ..
PU
2022CHMP Recommends Expansion of EU Label for Hemlibra to Include People with Moderate Hemo..
AQ
2022CHMP recommends expansion of EU label for Hemlibra to include people with moderate haem..
AQ
2022Interim data from phase III study presented at ASH 2022 show Hemlibra achieved meaningf..
AQ
2022Chugai and Towa Launch Edirol Tablet for Osteoporosis Treatment
AQ
2022Chugai Pharmaceutical Co., Ltd. - Transfer and Future Marketing of Osteoporosis Agent B..
AQ
2022Taisho Pharmaceutical Holdings Co., Ltd. (TSE:4581)..
CI
2022Chugai Pharmaceutical Co., Ltd. - Organizational and Personnel Changes
AQ
2022Chugai Pharmaceutical : Organizational and Personnel Changes
PU
2022Chugai Pharmaceutical Co., Ltd. - Contribution of Para-transit Vehicles to Welfare Serv..
AQ
2022Chugai Pharmaceutical and IBM Japan Initiate Operation of Digital Infrastructure at Uki..
AQ
2022Chugai Pharmaceutical Co., Ltd. - Purchase of Land for Business in Ukima
AQ
2022Chugai Pharmaceutical : Purchase of Land for Business in Ukima
PU
2022Chugai Announces 2022 3rd Quarter Results
AQ
2022Chugai Pharmaceutical's FY22 Nine-month Net Income Surges 33% on Significant Jump in Sa..
MT
2022Nikkei 225 Up 1% as Earnings Season Gets Underway
MT
2022Japanese stocks rise as Nidec's strong results boost earnings optimism
RE
2022Japanese stocks rise on boost from Nidec on strong earnings
RE
2022Global markets live: Tesla, Goldman Sachs, Mattel, Apple, Shell...
MS
2022Chugai Pharmaceutical : Supplementary Materials
PU
2022Chugai Pharmaceutical Co., Ltd. Provides Dividend Guidance for the Year Ending December..
CI
2022Chugai Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for Full Year o..
CI
2022Construction of Chugai's New Research Center 'Chugai Life Science Park Yokohama' Reache..
AQ
2022Chugai Pharmaceutical : 3Q Results (Jan-Sep 2022)
PU
2022Chugai Pharmaceutical : Construction of Chugai's New Research Center “Chugai Life Sc..
PU
2022Chugai Pharmaceutical Co., Ltd. - Relief Efforts Support for Season's Fifteenth Typhoon
AQ
2022Chugai Pharmaceutical : Files New Drug Application in Japan for Fixed-Dose Subcutaneous Co..
PU
2022Japan's Nikkei tracks Wall Street higher as Treasury yields fall
RE
2022Japan's Nikkei ends week on a high in hawkish climate
RE
2022Japanese stocks gain as investors digest cenbank decisions
RE
2022Chugai Pharmaceutical : Summary
PU
2022Roche's Japanese Unit Obtains Approval For Anticancer Medication
MT
2022Chugai Pharmaceutical : Obtains Regulatory Approval for POLIVY for Additional Indication o..
PU
2022Chugai Pharmaceutical : and Noile-Immune Biotech Enter into a License Agreement for Noile-..
PU
2022Chugai Pharmaceutical : Obtains Regulatory Approval for Osteoporosis Treatment Edirol Tabl..
PU
2022Chugai Pharmaceutical Co., Ltd. - Anti-C5 Recycling Antibody Crovalimab Obtains Priorit..
AQ
2022Roche's Rare Blood Disease Drug Wins Priority Review Tag In China
MT
2022Chugai Pharmaceutical : Anti-C5 Recycling Antibody Crovalimab Obtains Priority Review in C..
PU
2022Chugai Pharmaceutical Co., Ltd. - Notice of the Settlement of Patent Infringement Litig..
AQ
2022Chugai Pharmaceutical Co., Ltd. - Maruho Launched in Japan the Anti-IL-31 Receptor a Hu..
AQ
2022Chugai Pharmaceutical : Notice of the Settlement of Patent Infringement Litigation in the ..
PU
2022Roche's Chugai Unit Launches Skin Disease Drug in Japan
MT
2022Chugai Pharmaceutical : Maruho Launched in Japan the Anti-IL-31 Receptor A Humanized Monoc..
PU
2022Nikkei 225 Up 0.2% Ahead of Federal Reserve Announcement
MT
2022Nikkei inches lower while traders wait on Fed
RE
2022Chugai Pharmaceutical : Script (including Q&A)
PU
2022Chugai Pharmaceutical's Net Income Soars 73% on Higher Sales of New Products
MT
2022Chugai Pharmaceutical and Swiss Parent Tweak Basic Alliance Agreement Post Prime Market..
MT
2022Chugai Pharmaceutical Co., Ltd. - F. Hoffmann-La Roche Announces Half Year Results 2022
AQ
2022Chugai Pharmaceutical : Supplementary Materials for Consolidated Financial Results for the..
PU
2022Chugai Pharmaceutical : CONSOLIDATED FINANCIAL STATEMENTS (IFRS) (Non-Audited)(for the sec..
PU
2022Chugai Pharmaceutical : Announces 2022 Half Year Results
PU
2022Chugai Pharmaceutical : Personnel Changes
PU
2022Chugai Pharmaceutical : Partial Revision of the Basic Alliance Agreement with Roche
PU
2022Chugai Pharmaceutical : Supplementary Materials
PU
2022Chugai Pharmaceutical : 2Q Results (Jan-Jun 2022)
PU
2022Chugai Pharmaceutical Co., Ltd. Announces Dividend Guidance for the Year Ending Decembe..
CI
2022Chugai Pharmaceutical Co., Ltd. Announces Dividend for the Second Quarter Ending June 3..
CI
2022Chugai Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for Full Year o..
CI
2022Chugai Pharmaceutical Co., Ltd. Announces Partial Revision of the Basic Alliance Agreem..
CI
2022Dolphin Unit Closes $8 Million Purchase of High Reserve F&B in Cash-Stock Deal; Dolphin..
MT
2022Chugai Pharmaceutical : F. Hoffmann-La Roche Announces Half Year Results 2022
PU
2022Chugai Pharmaceutical : Conference on FY2022.12 2Q Financial Results
PU
2022Chugai's Osteoporosis Agent Edirol Launched in China
AQ
2022Chugai Pharmaceutical Continues to be Listed for All ESG Indices Selected by GPIF
AQ
2022Chugai Pharmaceutical Co., Ltd. - Primary Analysis of Japanese Phase III Clinical Trial..
AQ
2022Chugai Pharmaceutical Co., Ltd. - New Data from Phase III HAVEN 6 Study Reinforce Favor..
AQ
2022New data from phase III HAVEN 6 study reinforce favourable safety and efficacy profile ..
AQ
2022Chugai Pharmaceutical : Primary Analysis of Japanese Phase III Clinical Trial of Hemlibra ..
PU
1  2  3  4  5  6  7  8  9  10Next
Upcoming event on CHUGAI PHARMACEUTICAL CO., LTD